Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSC-derived exosomes + autologous mitochondria
- Development stage
- Unknown
- Lead developer
- Tehran University of Medical Sciences
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intra-arterial
01
Overview
This investigational therapy, developed by Tehran University of Medical Sciences, is a combination biologic treatment consisting of mesenchymal stem cell (MSC)-derived exosomes and autologous mitochondria. It is designed for patients with severe heart failure (LVEF ≤ 25%) undergoing coronary artery bypass grafting (CABG). The MSC-derived exosomes, which are biological nanovesicles, are intended to limit inflammatory damage, while the fresh autologous mitochondria (extracted from the patient's pectoralis muscle) are used to limit oxidative stress and restore cellular energy. The treatment aims to protect the myocardium against ischemia-reperfusion injury, preserve cardiac function, and reduce the zone of myocardial infarction. In clinical application, exosomes are administered via the coronary sinus, and mitochondria are injected directly into ischemic myocardial tissue.
- Other names
- MSC-derived exosomes and autologous mitochondriaMSC Exosomes and Mitochondria in CABG
Beyond the preview
Go deeper on MSC-derived exosomes + autologous mitochondria.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSC-derived exosomes + autologous mitochondria.